진행성 신장 세포 암종의 치료 관련 독성에 대한 소프트웨어 모니터링
2026년 4월 15일 업데이트: Chunkit Fung, University of Rochester
단일군 2상 타당성 연구인 Carevive 소프트웨어를 사용하여 진행성 신장 세포 암종(RCC) 환자의 경구 표적 약물 및 면역요법으로 인한 치료 관련 독성 모니터링
치료 관련 독성을 모니터링한 다음 이러한 증상에 대한 자가 관리 관리 계획을 생성하는 Carevive 소프트웨어가 전이성 신세포암종(RCC) 환자에게 구현 가능한지 확인합니다.
또한 치료 관련 독성, 삶의 질, 고통 수준 및 약물 순응도에 대한 예비 데이터를 수집합니다.
연구 개요
연구 유형
중재적
등록 (실제)
21
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
New York
-
Rochester, New York, 미국, 14642
- University of Rochester - Wilmot Cancer Institute
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
설명
포함 기준:
- 전이성 질환의 병리학적 또는 방사선학적 증거가 있는 모든 아형의 조직학적으로 확인된 신장 세포 암종의 진단
- 18세 이상
- 참여하는 Wilmot 암 센터 종양 전문의는 진행성 RCC 치료를 위해 후보자가 경구 표적 요법 또는 면역 요법을 시작해야 한다고 결정했습니다. 이는 1차 치료 또는 후속 치료에 사용될 수 있습니다.
- 서면 동의서를 제공할 수 있음
- 영어에 능숙하고 글을 읽을 줄 아는 것으로 스스로 보고합니다.
- 활성화된 이메일 주소가 있거나 문자 메시지를 받을 수 있는 스마트 장치에 대한 액세스 권한이 있어야 합니다.
제외 기준:
- 여성은 모유 수유를 할 수 없습니다
- 인터넷에 정기적으로 접속할 수 없습니다.
- 주 종양 전문의와의 정기 방문을 위해 3~4개월마다 Wilmot 암 센터에 방문할 수 없습니다.
- 이전에 연구에 참여한 피험자는 치료 변경 시 재등록이 허용되지 않습니다.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Carevive 소프트웨어 사용
진행성 신세포암종(RCC) 환자의 Carevive 소프트웨어를 통해 경구 표적 요법 또는 면역 요법으로 인한 부작용을 보고하고 관리합니다.
|
이번 연구에서 Carevive는 온라인 설문조사가 완료될 수 있도록 주제에 대한 링크를 제공할 예정입니다.
설문조사는 연구 첫 12주 동안 매주 실시되며 이후에는 격주로 실시됩니다.
질문은 주로 암 치료로 인한 부작용과 약물 순응도 및 의료 활용에 관한 몇 가지 질문에 중점을 둘 것입니다.
설문 조사가 완료된 후 피험자에게는 약물 관련 독성에 대한 집에서 자가 관리 옵션이 포함된 치료 계획이 제공됩니다.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants Who Submitted at Least One Carevive Survey
기간: From enrollment through 48 weeks
|
Number of participants who completed at least one Carevive survey at any time during the 48 week study period.
|
From enrollment through 48 weeks
|
|
Percentage of Carevive Surveys Completed Per Participant
기간: From enrollment through 48 weeks
|
Percentage of Carevive surveys completed by each participant, calculated as the number of completed surveys divided by the number of surveys prompted by the Carevive software during the 48 week study period.
|
From enrollment through 48 weeks
|
|
Number of Participants Who Utilized at Least One Auto-Generated Carevive Care Plan
기간: From enrollment through 48 weeks
|
Number of participants who accessed at least one auto-generated Carevive care plan at any time during the 48 week study period.
|
From enrollment through 48 weeks
|
|
Percentage of Auto Generated Carevive Care Plans Utilized Per Participant
기간: From enrollment through 48 weeks
|
Percentage of auto generated Carevive care plans utilized by each participant, calculated as the number of care plans accessed divided by the total number of care plans generated for that participant during the 48 week study period.
|
From enrollment through 48 weeks
|
|
System Usability Scale (SUS) Score for Carevive Software
기간: From enrollment through 48 weeks
|
Participants completed the System Usability Scale (SUS), which is a validated 10-item questionnaire that produces a total usability score ranging from 0 to 100.
Scores are categorized into three main categories: excellent (>80.3 points); good (68.0 to 80.3 points) and below average (<68 points).
We calculated the SUS point for each participant who completed the survey.
|
From enrollment through 48 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-DRS) Total Score
기간: From enrollment through 48 weeks
|
The FKSI-DRS is a validated patient-reported outcome measure assessing kidney cancer-related symptoms, with total scores ranging from 0 to 36, where higher scores indicate better quality of life.
|
From enrollment through 48 weeks
|
|
Distress Level Assessed by NCCN Distress Thermometer
기간: From enrollment through 48 weeks
|
The NCCN Distress Thermometer is a validated patient reported outcome measure assessing psychological distress on a scale from 0 to 10, with higher scores indicating greater distress.
Scores were categorized to reflect low distress (0-3) and moderate to severe distress (4-10).
|
From enrollment through 48 weeks
|
|
Health Care Utilization Assessment
기간: From enrollment through 48 weeks
|
Health care utilization was assessed based on participant self-report and defined as having at least one hospital visit, emergency room visit, or unplanned clinic visit during the 48-week study period.
|
From enrollment through 48 weeks
|
|
Participants Reporting Diarrhea
기간: From enrollment through 48 weeks
|
Number of participants who self reported Diarrhea (Yes or No) in response to PRO CTCAE survey questions assessing treatment related symptoms from oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Responses were collected using Carevive software surveys administered weekly for the first 12 weeks of the study and then every other week thereafter through 48 weeks.
Participants were counted as reporting this symptom if they answered "Yes" to the corresponding survey question during the specified time period.
|
From enrollment through 48 weeks
|
|
Participants Reporting Nausea
기간: From enrollment through 48 weeks
|
Number of participants who self reported nausea (Yes or No) in response to PRO CTCAE survey questions assessing treatment related toxicities from oral targeted agents and immunotherapy.
Responses were collected using Carevive surveys administered weekly for the first 12 weeks and then every other week for an additional 36 weeks.
Participants were counted as reporting the symptom if they answered "Yes" to the corresponding survey question during the specified time period.
|
From enrollment through 48 weeks
|
|
Participants Reporting Vomiting
기간: From enrollment through 48 weeks
|
Number of participants who self reported vomiting (Yes or No) in response to PRO CTCAE survey questions assessing treatment related toxicities from oral targeted agents and immunotherapy.
Responses were collected using Carevive surveys administered weekly for the first 12 weeks and then every other week for an additional 36 weeks.
Participants were counted as reporting the symptom if they answered "Yes" to the corresponding survey question during the specified time period.
|
From enrollment through 48 weeks
|
|
Participants Reporting Fatigue
기간: From enrollment through 48 weeks
|
Number of participants who self reported fatigue (Yes or No) in response to PRO CTCAE survey questions assessing treatment related toxicities from oral targeted agents and immunotherapy.
Responses were collected using Carevive surveys administered weekly for the first 12 weeks and then every other week for an additional 36 weeks.
Participants were counted as reporting the symptom if they answered "Yes" to the corresponding survey question during the specified time period.
|
From enrollment through 48 weeks
|
|
Participants Reporting Rash
기간: From enrollment through 48 weeks
|
Number of participants who self reported rash (Yes or No) in response to PRO CTCAE survey questions assessing treatment related symptoms from oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Responses were collected using Carevive software surveys administered weekly for the first 12 weeks of the study and then every other week thereafter through 48 weeks.
Participants were counted as reporting the symptom if they answered "Yes" to the corresponding survey question during the specified time period.
|
From enrollment through 48 weeks
|
|
Participants Reporting Abdominal Pain
기간: From enrollment through 48 weeks
|
Number of participants who self reported abdominal pain (Yes or No) in response to PRO CTCAE survey questions assessing treatment related symptoms from oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Responses were collected using Carevive software surveys administered weekly for the first 12 weeks of the study and then every other week thereafter through 48 weeks.
Participants were counted as reporting the symptom if they answered "Yes" to the corresponding survey question during the specified time period.
|
From enrollment through 48 weeks
|
|
Participants Reporting Mouth Sores
기간: From enrollment through 48 weeks
|
Number of participants who self reported mouth sores (Yes or No) in response to PRO CTCAE survey questions assessing treatment related symptoms from oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Responses were collected using Carevive software surveys administered weekly for the first 12 weeks of the study and then every other week thereafter through 48 weeks.
Participants were counted as reporting the symptom if they answered "Yes" to the corresponding survey question during the specified time period.
|
From enrollment through 48 weeks
|
|
Participants Reporting Cough
기간: From enrollment through 48 weeks
|
Number of participants who self reported cough (Yes or No) in response to PRO CTCAE survey questions assessing treatment related symptoms from oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Responses were collected using Carevive software surveys administered weekly for the first 12 weeks of the study and then every other week thereafter through 48 weeks.
Participants were counted as reporting the symptom if they answered "Yes" to the corresponding survey question during the specified time period.
|
From enrollment through 48 weeks
|
|
Participants Reporting Shortness of Breath
기간: From enrollment through 48 weeks
|
Number of participants who self reported Shortness of Breath (Yes or No) in response to PRO CTCAE survey questions assessing treatment related symptoms from oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Responses were collected using Carevive software surveys administered weekly for the first 12 weeks of the study and then every other week thereafter through 48 weeks.
Participants were counted as reporting the symptom if they answered "Yes" to the corresponding survey question during the specified time period.
|
From enrollment through 48 weeks
|
|
Participants Reporting Anorexia
기간: From enrollment through 48 weeks
|
Number of participants who self reported Anorexia (Yes or No) in response to PRO CTCAE survey questions assessing treatment related symptoms from oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Responses were collected using Carevive software surveys administered weekly for the first 12 weeks of the study and then every other week thereafter through 48 weeks.
Participants were counted as reporting this symptom if they answered "Yes" to the corresponding survey question during the specified time period.
|
From enrollment through 48 weeks
|
|
Clinician Reported Diarrhea
기간: From enrollment through 48 weeks
|
Number of participants with clinician reported diarrhea assessed during in office clinic visits while receiving oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Clinicians recorded the presence or absence of this symptom at baseline and during follow up assessments conducted from enrollment through 48 weeks.
Responses were categorized as Yes, No, or Unknown based on clinician assessment.
These data are presented as longitudinal assessments of symptom occurrence over time.
Summary reporting of these events as adverse events is provided separately in the Adverse Events section.
|
From enrollment through 48 weeks
|
|
Clinician Reported Nausea
기간: From enrollment through 48 weeks
|
Number of participants with clinician reported nausea assessed during in office clinic visits while receiving oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Clinicians recorded the presence or absence of this symptom at baseline and during follow up assessments conducted from enrollment through 48 weeks.
Responses were categorized as Yes, No, or Unknown based on clinician assessment.
These data are presented as longitudinal assessments of symptom occurrence over time.
Summary reporting of these events as adverse events is provided separately in the Adverse Events section.
|
From enrollment through 48 weeks
|
|
Clinician Reported Vomiting
기간: From enrollment through 48 weeks
|
Number of participants with clinician reported vomiting assessed during in office clinic visits while receiving oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Clinicians recorded the presence or absence of this symptom at baseline and during follow up assessments conducted from enrollment through 48 weeks.
Responses were categorized as Yes, No, or Unknown based on clinician assessment.
These data are presented as longitudinal assessments of symptom occurrence over time.
Summary reporting of these events as adverse events is provided separately in the Adverse Events section.
|
From enrollment through 48 weeks
|
|
Clinician Reported Fatigue
기간: From enrollment through 48 weeks
|
Number of participants with clinician reported fatigue assessed during in office clinic visits while receiving oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Clinicians recorded the presence or absence of this symptom at baseline and during follow up assessments conducted from enrollment through 48 weeks.
Responses were categorized as Yes, No, or Unknown based on clinician assessment.
These data are presented as longitudinal assessments of symptom occurrence over time.
Summary reporting of these events as adverse events is provided separately in the Adverse Events section.
|
From enrollment through 48 weeks
|
|
Clinician Reported Rash
기간: From enrollment through 48 weeks
|
Number of participants with clinician reported Rash assessed during in office clinic visits while receiving oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Clinicians recorded the presence or absence of this symptom at baseline and during follow up assessments conducted from enrollment through 48 weeks.
Responses were categorized as Yes, No, or Unknown based on clinician assessment.
These data are presented as longitudinal assessments of symptom occurrence over time.
Summary reporting of these events as adverse events is provided separately in the Adverse Events section.
|
From enrollment through 48 weeks
|
|
Clinician Reported Abdominal Pain
기간: From enrollment through 48 weeks
|
Number of participants with clinician reported Abdominal Pain assessed during in office clinic visits while receiving oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Clinicians recorded the presence or absence of this symptom at baseline and during follow up assessments conducted from enrollment through 48 weeks.
Responses were categorized as Yes, No, or Unknown based on clinician assessment.
These data are presented as longitudinal assessments of symptom occurrence over time.
Summary reporting of these events as adverse events is provided separately in the Adverse Events section.
|
From enrollment through 48 weeks
|
|
Clinician Reported Mouth Sores
기간: From enrollment through 48 weeks
|
Number of participants with clinician reported Mouth Sores assessed during in office clinic visits while receiving oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Clinicians recorded the presence or absence of this symptom at baseline and during follow up assessments conducted from enrollment through 48 weeks.
Responses were categorized as Yes, No, or Unknown based on clinician assessment.
These data are presented as longitudinal assessments of symptom occurrence over time.
Summary reporting of these events as adverse events is provided separately in the Adverse Events section.
|
From enrollment through 48 weeks
|
|
Clinician Reported Cough
기간: From enrollment through 48 weeks
|
Number of participants with clinician reported Cough assessed during in office clinic visits while receiving oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Clinicians recorded the presence or absence of this symptom at baseline and during follow up assessments conducted from enrollment through 48 weeks.
Responses were categorized as Yes, No, or Unknown based on clinician assessment.
These data are presented as longitudinal assessments of symptom occurrence over time.
Summary reporting of these events as adverse events is provided separately in the Adverse Events section.
|
From enrollment through 48 weeks
|
|
Clinician Reported Shortness of Breath
기간: From enrollment through 48 weeks
|
Number of participants with clinician reported Shortness of Breath assessed during in office clinic visits while receiving oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Clinicians recorded the presence or absence of this symptom at baseline and during follow up assessments conducted from enrollment through 48 weeks.
Responses were categorized as Yes, No, or Unknown based on clinician assessment.
These data are presented as longitudinal assessments of symptom occurrence over time.
Summary reporting of these events as adverse events is provided separately in the Adverse Events section.
|
From enrollment through 48 weeks
|
|
Clinician Reported Anorexia
기간: From enrollment through 48 weeks
|
Number of participants with clinician reported Anorexia assessed during in office clinic visits while receiving oral targeted therapy or immunotherapy for advanced renal cell carcinoma.
Clinicians recorded the presence or absence of this symptom at baseline and during follow up assessments conducted from enrollment through 48 weeks.
Responses were categorized as Yes, No, or Unknown based on clinician assessment.
These data are presented as longitudinal assessments of symptom occurrence over time.
Summary reporting of these events as adverse events is provided separately in the Adverse Events section.
|
From enrollment through 48 weeks
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2019년 7월 24일
기본 완료 (실제)
2025년 2월 14일
연구 완료 (실제)
2025년 2월 14일
연구 등록 날짜
최초 제출
2017년 7월 18일
QC 기준을 충족하는 최초 제출
2017년 7월 24일
처음 게시됨 (실제)
2017년 7월 25일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 5월 7일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 4월 15일
마지막으로 확인됨
2025년 2월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- UGUK 17036
- UG1CA189961 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
미국에서 제조되어 미국에서 수출되는 제품
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
진행성 신장 세포 암종에 대한 임상 시험
-
Taichung Veterans General Hospital완전한심장 독성 | 비소세포폐암 (MeSH 용어: Carcinoma, Non-Small-Cell Lung) | 의약품 관련 부작용 및 이상반응 (MeSH 용어) | Egfr 티로신 키나아제 억제제대만
-
Fondazione del Piemonte per l'Oncologia모병유방암 | 난소 암 | 대장암 | 흑색종(피부암) | 비소세포폐암 (MeSH 용어: Carcinoma, Non-Small-Cell Lung)이탈리아
케어바이브 소프트웨어에 대한 임상 시험
-
University of Alabama at BirminghamAmerican Cancer Society, Inc.; Carevive Systems, Inc.완전한
-
Human Service Center, Illinois알려지지 않은
-
Essilor International모병